Nanoparticle approaches for the renin-angiotensin system

Sajini D Hettiarachchi1, Young M Kwon1, Yadollah Omidi1

  • 1Department of Pharmaceutical Sciences, Barry and Judy College of Pharmacy, Nova Southeastern University, 3200 S University Dr, Davie, FL, 33328 USA.

Heliyon
|July 24, 2023
PubMed

Insights

Nanoparticle drug delivery systems offer a promising solution to overcome limitations of current renin-angiotensin system (RAS) inhibitors. These nano-scale systems enhance drug efficacy and reduce toxicity for treating RAS-related disorders.

Area of Science:

  • Biomedical Engineering
  • Pharmacology
  • Nanotechnology

Background:

  • The renin-angiotensin system (RAS) plays a critical role in systemic hypertension, heart failure, kidney disease, and neurodegenerative disorders.
  • RAS activation can exacerbate inflammation and fibrosis, contributing to disease progression.
  • Current RAS-inhibiting drugs face challenges including poor blood-brain barrier penetration, low bioavailability, and short half-lives.

Purpose of the Study:

  • To review nanoparticle-mediated drug delivery systems (DDSs) as potential alternatives to overcome limitations of conventional RAS inhibitors.
  • To summarize the physical and chemical characteristics of various nanoparticles for RAS-related applications.
  • To elaborate on the potential clinical applications of nano-scale DDSs in managing RAS-associated diseases.

Main Methods:

  • Review of existing literature on nanoparticle DDSs and their application in targeting the renin-angiotensin system.
  • Analysis of nanoparticle characteristics such as size, water dispersity, circulation half-life, and biocompatibility.
  • Examination of different nanoparticle types, including chitosan, polymeric, and nanofibers, used in RAS-related studies.

Main Results:

  • Nanoparticle DDSs exhibit unique characteristics like smaller size (1-100 nm), enhanced water dispersity, prolonged circulation, and biocompatibility.
  • Nano-scale DDSs can potentially reduce drug dosage frequency and acute toxicity while improving therapeutic outcomes.
  • Various nanoparticles have shown promise in studies related to hypertension, cardiovascular disease, and COVID-19, all involving RAS.

Conclusions:

  • Nanoparticle-mediated DDSs represent a significant advancement for RAS-targeted therapies, addressing limitations of traditional drugs.
  • The unique properties of nanoparticles offer enhanced efficacy and safety profiles for treating a range of RAS-related conditions.
  • Further research into the physical and chemical properties of nanoparticles is crucial for optimizing their use in clinical applications for RAS disorders.

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
695
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
693
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
784